Epiretinal MembraneNCT02691429
Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans
A study testing Acai dye 10% in people with Epiretinal Membrane and Macular Hole, run by Federal University of São Paulo at 1 site in Brazil.
Trial summary
Our research group tested the toxicity of different dye concentrations extracted from the acai fruit using a rabbit model. The dye extracted from the acai fruit in concentrations of 10% and 25% was found to be safe for vitreoretinal surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Epiretinal Membrane, Macular Hole, Diabetic Retinopathy
- What is being tested?
- Acai dye 10%
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteBrazil
- Study dates
- Feb 2016to May 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with epiretinal membrane, macular hole or proliferative diabetic retinopathy (with or without vitreous hemorrhage).
- Indicated for surgical removal of the epiretinal memebrane (with or without removal of the internal limiting membrane).
Who cannot join
- - Previous ocular pathology
- Glaucoma
- Any other previous ocular infection that would modify ocular anatomy.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Dept of Ophthalmology - UNIFESP/Hospital São Paulo
São Paulo, São Paulo, 04023-062
About this study
Our research group tested the toxicity of different dye concentrations extracted from the acai fruit using a rabbit model. The dye extracted from the acai fruit in concentrations of 10% and 25% was found to be safe for vitreoretinal surgery. This initial research represented the landmark research for testing this alternative vital dye in a clinical research in humans.
The aim of the present clinical trial in humans will be to test the applicability of the acai dye in the identification of the posterior hyaloid and ILM during vitreoretinal surgery in humans.
Read the detailed description
The purpose of the present clinical trial in humans will be to test the impregnation capacity of the acai dye (10 and 25% concentrations) in the identification of the posterior hyaloid and ILM during vitreoretinal surgery in humans.
Twenty-four patients that seek treatment at the Ophthalmology Department of The Federal University of São Paulo will be selected for this study. Inclusion criteria will be patients diagnosed with epiretinal membrane, macular hole or diabetic retinopathy (with or without vitreal hemorrhages, and/or macular edema, and/or vitreomacular traction). All must be indicated for vitrectomy surgery for the removal of the epiretinal membrane and/or internal limiting membrane.
The present clinical trial was approved by the ethics committee of the Federal University of São Paulo (CEP-UNIFESP). All patients will be invited to sign an Informed Consent Form before participating in the study.
Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in.
All patients will be submitted to the following routine pre-operatory evaluations:
- Physical and pre-anesthesia evaluations - to be performed by the Anesthesiology Team of the São Paulo Hospital.
- Complete Ophthalmological Examination - that will include:
- Visual Acuity Measurements with best correction for both eyes.
- Applaination Tonometry (Goldman Tonometer). For this, one drop of anesthetic solution and one drop of fluorescein were instilled in the eye.
- Biomicroscopy
- Indirect binocular ophthalmoscopy: under mydriasis that will be obtained before each procedure by topical application of tropicamide and phenylephrine.
- Retinography and Angiofluoresceinography (with patient under mydriasis- except when "opacidade de meios")
- Optical Coherence Tomography (OCT) of the posterior segment (except when "opacidade de meios")
- Multifocal Electroretinogram (except when "opacidade de meios")
The vitrectomy surgery will be performed in all patients of this present study using the 23-gauge technique composed of 4 sclerectomies and vitrectomy without 23-gauge sutures.
During surgery, after vitreous removal, the dye extracted from the acai fruit will be slowly injected using a 23 or 25-gauge silicone cannula connected to a 5ml syringe. The objective of the slow injection of the dye is so that it will deposit over the posterior hyloid/peripheral vitreous due to gravity. At this moment, photographic documentation will be performed.
After the dislocation of the posterior hyloid, the removal of the peripheral vitreous and the excess dye, a MachemerTM (Volk, Germany) macula magnifying lens will be used to improve visualization for the removal of the ILM using an intraocular tweezers. If the ILM is not visible, a second injection with the dye will be performed.
At the end of the surgery, all patients will receive medical prescription of drops with antibiotic and corticoid association during 1 week after the procedure, following vitrectomy post-surgical routine.
A questionnaire with 6 questions (ANNEX 1) will be handed to each surgeon after the end of the surgery.
- Conditions
- Epiretinal Membrane, Macular Hole, Diabetic Retinopathy
- Being tested
- Acai dye 10%
- Keywords
- Vitreoretinal surgery, euterpe oleracea, chromovitrectomy
- Medical subject headings
- Epiretinal Membrane, Retinal Perforations, Diabetic Retinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acai dye 10%Other
Also called euterpe oleracea dye
dye to be used during chromovitrectomy in humans
| Study group | Role | What they receive |
|---|---|---|
| acai dye (Euterpe oleracea) 10% | Active comparator | Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in Receives: Other: Acai dye 10% |
| acai dye (Euterpe oleracea) 25% | Active comparator | Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in Receives: Other: Acai dye 10% |
What is being measured
The primary outcome is the main question the study is designed to answer.
ocular inflammation
signs of ocular inflammation
Measured: up to 30 days
Secondary outcomes (2)
intraocular pressure
increase of intraocular pressure
Measured: up to 30 days
complications of the posterior segment
macular edema
Measured: up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2016 (estimated)
- Study startFeb 2016
- Primary completionNov 2016
- Study completionMay 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Epiretinal MembraneStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Federal University of São Paulo
- Sponsor type
- University, hospital or other
- Collaborators
- Rafael R. Caiado, Casa de Saúde São José, Acácio Alves Souza Lima-Filho, Eduardo Novais, Emmerson Badaró, André Maia, Rita Sinigaglia-Coimbra, Sung Eun S. Watanabe, Eduardo B. Rodrigues, Michel Eid Farah, Mauricio Maia
- Responsible party
- Principal investigator, Mauricio Maia, Federal University of São Paulo
- Investigators
- Mauricio Maia, Principal investigator, Federal University of São Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02691429
- Sponsor's protocol ID
- ACAI_2015
- Status last verified
- Jun 2017
- First submitted
- 22 Feb 2016
- Last updated
- 7 Jun 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans
- ClinicalTrials.gov ID
- NCT02691429
- Acronym / sponsor ID
- ACAI_2015
- Conditions
- Epiretinal Membrane, Macular Hole, Diabetic Retinopathy
- Keywords
- Vitreoretinal surgery, euterpe oleracea, chromovitrectomy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Federal University of São PauloUniversity, hospital or other
- Collaborators
- Rafael R. Caiado, Casa de Saúde São José, Acácio Alves Souza Lima-Filho, Eduardo Novais, Emmerson Badaró, André Maia, Rita Sinigaglia-Coimbra, Sung Eun S. Watanabe, Eduardo B. Rodrigues, Michel Eid Farah, Mauricio Maia
- Study start
- Feb 2016
- Primary completion
- Nov 2016 (actual)
- Study completion
- May 2017 (actual)
- First posted
- 25 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our research group tested the toxicity of different dye concentrations extracted from the acai fruit using a rabbit model. The dye extracted from the acai fruit in concentrations of 10% and 25% was found to be safe for vitreoretinal surgery. This initial research represented the landmark research for testing this alternative vital dye in a clinical research in humans.
The aim of the present clinical trial in humans will be to test the applicability of the acai dye in the identification of the posterior hyaloid and ILM during vitreoretinal surgery in humans.
Detailed description
The purpose of the present clinical trial in humans will be to test the impregnation capacity of the acai dye (10 and 25% concentrations) in the identification of the posterior hyaloid and ILM during vitreoretinal surgery in humans.
Twenty-four patients that seek treatment at the Ophthalmology Department of The Federal University of São Paulo will be selected for this study. Inclusion criteria will be patients diagnosed with epiretinal membrane, macular hole or diabetic retinopathy (with or without vitreal hemorrhages, and/or macular edema, and/or vitreomacular traction). All must be indicated for vitrectomy surgery for the removal of the epiretinal membrane and/or internal limiting membrane.
The present clinical trial was approved by the ethics committee of the Federal University of São Paulo (CEP-UNIFESP). All patients will be invited to sign an Informed Consent Form before participating in the study.
Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in.
All patients will be submitted to the following routine pre-operatory evaluations:
- Physical and pre-anesthesia evaluations - to be performed by the Anesthesiology Team of the São Paulo Hospital.
- Complete Ophthalmological Examination - that will include:
- Visual Acuity Measurements with best correction for both eyes.
- Applaination Tonometry (Goldman Tonometer). For this, one drop of anesthetic solution and one drop of fluorescein were instilled in the eye.
- Biomicroscopy
- Indirect binocular ophthalmoscopy: under mydriasis that will be obtained before each procedure by topical application of tropicamide and phenylephrine.
- Retinography and Angiofluoresceinography (with patient under mydriasis- except when "opacidade de meios")
- Optical Coherence Tomography (OCT) of the posterior segment (except when "opacidade de meios")
- Multifocal Electroretinogram (except when "opacidade de meios")
The vitrectomy surgery will be performed in all patients of this present study using the 23-gauge technique composed of 4 sclerectomies and vitrectomy without 23-gauge sutures.
During surgery, after vitreous removal, the dye extracted from the acai fruit will be slowly injected using a 23 or 25-gauge silicone cannula connected to a 5ml syringe. The objective of the slow injection of the dye is so that it will deposit over the posterior hyloid/peripheral vitreous due to gravity. At this moment, photographic documentation will be performed.
After the dislocation of the posterior hyloid, the removal of the peripheral vitreous and the excess dye, a MachemerTM (Volk, Germany) macula magnifying lens will be used to improve visualization for the removal of the ILM using an intraocular tweezers. If the ILM is not visible, a second injection with the dye will be performed.
At the end of the surgery, all patients will receive medical prescription of drops with antibiotic and corticoid association during 1 week after the procedure, following vitrectomy post-surgical routine.
A questionnaire with 6 questions (ANNEX 1) will be handed to each surgeon after the end of the surgery.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| acai dye (Euterpe oleracea) 10% | Active comparator | Other: Acai dye 10%Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12). Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in |
| acai dye (Euterpe oleracea) 25% | Active comparator | Other: Acai dye 10%Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12). Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Diagnosed with epiretinal membrane, macular hole or proliferative diabetic retinopathy (with or without vitreous hemorrhage).
- Indicated for surgical removal of the epiretinal memebrane (with or without removal of the internal limiting membrane).
Key exclusion criteria (3 listed)
- - Previous ocular pathology
- Glaucoma
- Any other previous ocular infection that would modify ocular anatomy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acai dye 10%Also: euterpe oleracea dyedye to be used during chromovitrectomy in humans | Other | acai dye (Euterpe oleracea) 10%, acai dye (Euterpe oleracea) 25% |
Primary outcome
ocular inflammation
Time frame: up to 30 days
signs of ocular inflammation
2 secondary outcomes
intraocular pressure
Time frame: up to 30 days
complications of the posterior segment
Time frame: up to 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jun 2017.
- Individual participant dataSharing planned: No
Related trials for Epiretinal Membrane
Recruiting
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
Epiretinal Membrane
RecruitingObservational study
Surgical Procedure Efficiency Evaluation stuDy
Cataract, Vitreous Hemorrhage
RecruitingObservational study
Intraoperative OCT Guidance of Intraocular Surgery II
Macular Holes, Epiretinal Membrane
Not yet recruitingObservational study
OCT Macula Biomarkers Before Silicone Oil Removal and Visual Outcome After Silicone Oil Removal
Retinal Detachment, Macular Edema
Recruiting
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
Epiretinal Membrane, Dry Age Related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mauricio Maia principal investigator
Federal University of São Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acai dye 10% in people with Epiretinal Membrane and Macular Hole, run by Federal University of São Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ocular inflammation (time frame: up to 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2017.